TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
10x Genomics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Products and services revenue | $596.69M | $610.46M | $618.73M | – | – | – | – | – | – | 92.8% | -2.3% |
| Consumables | $507.18M | $493.43M | $479.55M | $435.59M | $418.74M | $252.69M | $206.88M | $107.62M | $46.19M | 78.9% | +2.8% |
| Single Cell | $363.21M | $372.31M | $420.32M | – | – | – | – | – | – | 56.5% | -2.4% |
| Spatial | $143.98M | $121.12M | $59.24M | $35.16M | $27.86M | – | – | – | – | 22.4% | +18.9% |
| Instruments | $56.78M | $92.72M | $123.47M | $72.40M | $64.47M | – | – | – | – | 8.8% | -38.8% |
| License and royalty revenue | $46.14M | $321.00K | $0 | – | – | – | – | – | – | 7.2% | +14272.3% |
| Spatial | $34.11M | $57.50M | $75.61M | $13.84M | $303.00K | – | – | – | – | 5.3% | -40.7% |
| Services | $32.73M | $24.32M | $15.70M | $8.43M | $7.28M | $6.03M | $4.07M | $2.16M | $426.00K | 5.1% | +34.6% |
| Single Cell | $22.67M | $35.21M | $47.87M | – | – | – | – | – | – | 3.5% | -35.6% |
| Instruments | – | – | – | $72.40M | $64.47M | $40.13M | $34.95M | $36.54M | $24.47M | – | – |
| Single Cell | – | $35.21M | $47.87M | $58.55M | $64.17M | – | – | – | – | – | – |
| Single Cell | – | $372.31M | $420.32M | $400.43M | $390.88M | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $358.77M | $347.77M | $373.19M | $293.78M | $264.99M | – | – | – | – | 55.8% | +3.2% |
| United States | $346.51M | $334.32M | $360.09M | $284.99M | $258.27M | $154.77M | $133.27M | – | – | 53.9% | +3.6% |
| Europe, Middle East and Africa | $161.72M | $159.76M | $142.28M | $117.07M | $108.49M | $73.27M | $58.00M | $35.81M | $18.60M | 25.2% | +1.2% |
| Asia-Pacific | $122.33M | $103.26M | $103.26M | $105.56M | $117.01M | $24.51M | $18.21M | $10.29M | $5.69M | 19.0% | +18.5% |
| China | $70.26M | $57.30M | $50.97M | $64.36M | $77.90M | $41.74M | $29.92M | $15.08M | $3.17M | 10.9% | +22.6% |
| Asia-Pacific (excluding China) | $52.07M | $45.96M | $52.29M | $41.21M | $39.11M | – | – | – | – | 8.1% | +13.3% |
| Americas (excluding United States) | $12.26M | $13.45M | $13.10M | $8.79M | $6.71M | – | – | – | – | 1.9% | -8.8% |
| North America | – | – | – | – | – | $159.33M | $139.76M | $85.13M | $43.62M | – | – |
| North America (excluding United States) | – | – | – | $8.79M | $6.71M | $4.56M | $6.49M | – | – | – | – |
From the segment and revenue-disaggregation notes of 10x Genomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.